BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
What to watch for as NASA’s historic Artemis II crew prepares to lift off toward the moon - 2Hidden Island Cameras Capture Rare Tasmanian Species for the First Time Ever
- 35 Side interests That Work on Psychological wellness
- 415 Preposterous Cosplay Ensembles That Will Blow You Away
- 5What to watch for in weight loss drugs in 2026
- Why the weirdest sea level changes on Earth are happening off the coast of Japan
- Saucony's $125 'Comfy, Stylish' Sneakers Are Now $55
- Swap The Amalfi Coast For This Low-Cost Ligurian Seaside Town
- Exclusive-Drugmakers raise US prices on 350 medicines despite pressure from Trump
- Pentagon advances Golden Dome missile defense with new Space Force contracts
- Defense Minister Katz finally condemns Jewish extremist violence against Palestinians
- Pick Your Favored kind of soup
- The most effective method to Keep up with Proficient Handshakes in a Computerized World
- Knesset FADC extends emergency draft for 280,000 IDF reservists until January 1
